Pfizer Highlights 'Unprecedented' 5 Year Data From Cancer Drug In Rare Form Of Advanced Lung Cancer
Portfolio Pulse from Vandana Singh
Pfizer Inc (NYSE:PFE) released promising five-year follow-up results from the Phase 3 CROWN trial for its cancer drug Lorbrena, showing significant improvements in progression-free survival and intracranial progression compared to Xalkori. The company expects Lorbrena to generate over $1 billion in annual sales by 2030.
May 31, 2024 | 6:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Pfizer's Lorbrena demonstrated significant improvements in progression-free survival and intracranial progression in a five-year follow-up study, outperforming Xalkori. Pfizer expects Lorbrena to generate over $1 billion in annual sales by 2030.
The positive results from the CROWN trial indicate that Lorbrena is significantly more effective than Xalkori in treating ALK-positive advanced NSCLC. This is likely to boost investor confidence and drive up Pfizer's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100